APA

Bayraktar S., Royce M., Stork-Sloots L., de Snoo F. & Glück S. (20151117). Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy. : Medical oncology (Northwood, London, England).

Chicago

Bayraktar Soley, Royce Melanie, Stork-Sloots Lisette, de Snoo Femke and Glück Stefan. 20151117. Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy. : Medical oncology (Northwood, London, England).

Harvard

Bayraktar S., Royce M., Stork-Sloots L., de Snoo F. and Glück S. (20151117). Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy. : Medical oncology (Northwood, London, England).

MLA

Bayraktar Soley, Royce Melanie, Stork-Sloots Lisette, de Snoo Femke and Glück Stefan. Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy. : Medical oncology (Northwood, London, England). 20151117.